BEIGENE Reports Q1 2026 Net Profit of 1.608 Billion Yuan

Stock News05-06 19:41

BEIGENE (688235.SH) announced its financial results for the first quarter of 2026. The company reported product revenue of 10.321 billion yuan, representing a year-on-year increase of 29.3%. Total operating revenue for the quarter reached 10.544 billion yuan, up 31.0% compared to the same period last year. Net profit attributable to owners of the parent company was 1.608 billion yuan.

As of the end of the reporting period, the company's total assets stood at 59.069 billion yuan, an increase of 3.1% from the beginning of the period. Equity attributable to owners of the parent company was 33.031 billion yuan, rising 7.8% from the start of the quarter.

The growth in product revenue, which increased from 7.985 billion yuan in the prior-year period to 10.321 billion yuan, was primarily driven by increased sales of BRUKINSA® (zanubrutinib), products licensed from Amgen, and TEVIMBRA® (tislelizumab).

In the first quarter of 2026, global sales of BRUKINSA totaled 7.598 billion yuan, a year-on-year increase of 33.5%. The United States remained the company's largest commercial market, with sales reaching 5.283 billion yuan, up 30.8%. Sales in Europe totaled 1.266 billion yuan, growing 51.4%, while sales in China amounted to 651 million yuan, increasing 10.4%.

Global sales of TEVIMBRA for the quarter totaled 1.429 billion yuan, a 14.8% year-on-year increase. Sales of products licensed from Amgen reached 989 million yuan, rising 20.9% compared to the first quarter of 2025.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1165111253?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-06 19:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1165111253","market":"hk","top_or_hot":-1,"title":"BEIGENE Reports Q1 2026 Net Profit of 1.608 Billion Yuan","media":"Stock News","content":"<p>BEIGENE (688235.SH) announced its financial results for the first quarter of 2026. The company reported product revenue of 10.321 billion yuan, representing a year-on-year increase of 29.3%. Total operating revenue for the quarter reached 10.544 billion yuan, up 31.0% compared to the same period last year. Net profit attributable to owners of the parent company was 1.608 billion yuan.</p>\n<p>As of the end of the reporting period, the company's total assets stood at 59.069 billion yuan, an increase of 3.1% from the beginning of the period. Equity attributable to owners of the parent company was 33.031 billion yuan, rising 7.8% from the start of the quarter.</p>\n<p>The growth in product revenue, which increased from 7.985 billion yuan in the prior-year period to 10.321 billion yuan, was primarily driven by increased sales of BRUKINSA® (zanubrutinib), products licensed from Amgen, and TEVIMBRA® (tislelizumab).</p>\n<p>In the first quarter of 2026, global sales of BRUKINSA totaled 7.598 billion yuan, a year-on-year increase of 33.5%. The United States remained the company's largest commercial market, with sales reaching 5.283 billion yuan, up 30.8%. Sales in Europe totaled 1.266 billion yuan, growing 51.4%, while sales in China amounted to 651 million yuan, increasing 10.4%.</p>\n<p>Global sales of TEVIMBRA for the quarter totaled 1.429 billion yuan, a 14.8% year-on-year increase. Sales of products licensed from Amgen reached 989 million yuan, rising 20.9% compared to the first quarter of 2025.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BEIGENE Reports Q1 2026 Net Profit of 1.608 Billion Yuan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBEIGENE Reports Q1 2026 Net Profit of 1.608 Billion Yuan\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-05-06 19:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BEIGENE (688235.SH) announced its financial results for the first quarter of 2026. The company reported product revenue of 10.321 billion yuan, representing a year-on-year increase of 29.3%. Total operating revenue for the quarter reached 10.544 billion yuan, up 31.0% compared to the same period last year. Net profit attributable to owners of the parent company was 1.608 billion yuan.</p>\n<p>As of the end of the reporting period, the company's total assets stood at 59.069 billion yuan, an increase of 3.1% from the beginning of the period. Equity attributable to owners of the parent company was 33.031 billion yuan, rising 7.8% from the start of the quarter.</p>\n<p>The growth in product revenue, which increased from 7.985 billion yuan in the prior-year period to 10.321 billion yuan, was primarily driven by increased sales of BRUKINSA® (zanubrutinib), products licensed from Amgen, and TEVIMBRA® (tislelizumab).</p>\n<p>In the first quarter of 2026, global sales of BRUKINSA totaled 7.598 billion yuan, a year-on-year increase of 33.5%. The United States remained the company's largest commercial market, with sales reaching 5.283 billion yuan, up 30.8%. Sales in Europe totaled 1.266 billion yuan, growing 51.4%, while sales in China amounted to 651 million yuan, increasing 10.4%.</p>\n<p>Global sales of TEVIMBRA for the quarter totaled 1.429 billion yuan, a 14.8% year-on-year increase. Sales of products licensed from Amgen reached 989 million yuan, rising 20.9% compared to the first quarter of 2025.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1588","symbol_name":"回港中概股","start_time":0,"source_url":"","article_id":"1165111253","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1165111253","pubTimestamp":1778067701,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"BEIGENE (688235.SH) announced its financial results for the first quarter of 2026. The company reported product revenue of 10.321 billion yuan, representing a year-on-year increase of 29.3%. Total...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688235":"百济神州","BK1588":"回港中概股","BK1161":"生物科技","LU1770034418.SGD":"ALL CHINA EQUITY \"A\" (SGDHDG) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","ONC":"百济神州","BK4585":"ETF&股票定投概念","BK4526":"热门中概股","06160":"百济神州","BK4139":"生物科技","LU0307460666.USD":"EASTSPRING INVESTMENTS CHINA EQUITY \"A\" ACC","BK0239":"医药制造","BK1583":"高瓴概念","LU0588546209.SGD":"Eastspring Investments - China Equity Fund AS SGD","LU1251922891.USD":"NINETY ONE GSF ALL CHINA EQUITY \"A\" (USD) ACC","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","BK4588":"碎股","BK1500":"做空集合股","LU1303224171.USD":"NINETY ONE GSF ALL CHINA EQUITY \"A\" (USD) INC","LU1719994722.HKD":"NINETY ONE GSF ALL CHINA EQUITY \"A\" (HKD) ACC"},"translate_title":"百济神州2026年Q1净利润16.08亿元","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688235":1,"ONC":1,"06160":1},"content_text":"BEIGENE (688235.SH) announced its financial results for the first quarter of 2026. The company reported product revenue of 10.321 billion yuan, representing a year-on-year increase of 29.3%. Total operating revenue for the quarter reached 10.544 billion yuan, up 31.0% compared to the same period last year. Net profit attributable to owners of the parent company was 1.608 billion yuan.\nAs of the end of the reporting period, the company's total assets stood at 59.069 billion yuan, an increase of 3.1% from the beginning of the period. Equity attributable to owners of the parent company was 33.031 billion yuan, rising 7.8% from the start of the quarter.\nThe growth in product revenue, which increased from 7.985 billion yuan in the prior-year period to 10.321 billion yuan, was primarily driven by increased sales of BRUKINSA® (zanubrutinib), products licensed from Amgen, and TEVIMBRA® (tislelizumab).\nIn the first quarter of 2026, global sales of BRUKINSA totaled 7.598 billion yuan, a year-on-year increase of 33.5%. The United States remained the company's largest commercial market, with sales reaching 5.283 billion yuan, up 30.8%. Sales in Europe totaled 1.266 billion yuan, growing 51.4%, while sales in China amounted to 651 million yuan, increasing 10.4%.\nGlobal sales of TEVIMBRA for the quarter totaled 1.429 billion yuan, a 14.8% year-on-year increase. Sales of products licensed from Amgen reached 989 million yuan, rising 20.9% compared to the first quarter of 2025.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1165111253","isCrawlerRequest":true}